FDA Says to Drop Suicide Warning From GLP-1 Drug Labels

(MedPage Today) — The FDA requested that manufacturers of GLP-1 receptor agonists remove information regarding risks of suicidal behavior and ideation from drug labels following a detailed review of existing data, the agency announced on Tuesday…

Source link : https://www.medpagetoday.com/primarycare/obesity/119405

Author :

Publish date : 2026-01-13 20:43:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

FDA Says to Drop Suicide Warning From GLP-1 Drug Labels

Mystery Brain Disease in Canada; Alzheimer’s Clinical Trial Lawsuit; Brains in Space

Rare Childhood Disorder Gets Its First FDA Drug Approval

Related Posts

Rare Childhood Disorder Gets Its First FDA Drug Approval

Mystery Brain Disease in Canada; Alzheimer’s Clinical Trial Lawsuit; Brains in Space

‘Misleading’ Heart Drug Ad; JenaValve Deal Thwarted; SGLT2 Inhibitor to Prevent HF

Streeting Moves to Favour UK Graduates for NHS Training

EPA Will Stop Calculating the Economic Savings to Health in Key Air Pollution Rules

Nurses Strike Enters Second Day at Major New York City Hospitals

Rare Childhood Disorder Gets Its First FDA Drug Approval

FDA Says to Drop Suicide Warning From GLP-1 Drug Labels

Mystery Brain Disease in Canada; Alzheimer’s Clinical Trial Lawsuit; Brains in Space

‘Misleading’ Heart Drug Ad; JenaValve Deal Thwarted; SGLT2 Inhibitor to Prevent HF

Streeting Moves to Favour UK Graduates for NHS Training

EPA Will Stop Calculating the Economic Savings to Health in Key Air Pollution Rules

Nurses Strike Enters Second Day at Major New York City Hospitals

Trump Talks About Taking GLP-1s; New MiniMed System OK’d; Testosterone in Diet Recs

Categories

Archives